UA113409C2 - Солі азабіциклічних діарилових ефірів та способи їх одержання або одержання їх попередників - Google Patents

Солі азабіциклічних діарилових ефірів та способи їх одержання або одержання їх попередників

Info

Publication number
UA113409C2
UA113409C2 UAA201314891A UAA201314891A UA113409C2 UA 113409 C2 UA113409 C2 UA 113409C2 UA A201314891 A UAA201314891 A UA A201314891A UA A201314891 A UAA201314891 A UA A201314891A UA 113409 C2 UA113409 C2 UA 113409C2
Authority
UA
Ukraine
Prior art keywords
preparation
precursors
salts
methods
azabicyclic
Prior art date
Application number
UAA201314891A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113409(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA113409C2 publication Critical patent/UA113409C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Даний винахід стосується солей (R)-3-(6-(4-метилфеніл)піридин-3-ілоксі)-1-азабіцикло[2.2.2]октану, способів їх одержання або одержання їх попередників, фармацевтичних композицій, що їх містять, та їх використання як лікарських засобів.
UAA201314891A 2011-07-15 2012-12-07 Солі азабіциклічних діарилових ефірів та способи їх одержання або одержання їх попередників UA113409C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161508147P 2011-07-15 2011-07-15
PCT/EP2012/063712 WO2013010916A1 (en) 2011-07-15 2012-07-12 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Publications (1)

Publication Number Publication Date
UA113409C2 true UA113409C2 (xx) 2017-01-25

Family

ID=45478332

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201314891A UA113409C2 (xx) 2011-07-15 2012-12-07 Солі азабіциклічних діарилових ефірів та способи їх одержання або одержання їх попередників

Country Status (28)

Country Link
US (3) US9365565B2 (uk)
EP (2) EP2731946B1 (uk)
JP (2) JP6263469B2 (uk)
KR (3) KR101846770B1 (uk)
CN (2) CN103717596B (uk)
AR (1) AR087164A1 (uk)
AU (1) AU2012285943B2 (uk)
BR (1) BR112014000907A2 (uk)
CA (1) CA2841546C (uk)
CL (1) CL2014000119A1 (uk)
CO (1) CO6852078A2 (uk)
EA (1) EA025477B1 (uk)
ES (1) ES2611950T3 (uk)
GT (1) GT201400007A (uk)
HK (1) HK1249505A1 (uk)
HU (1) HUE031256T2 (uk)
IL (2) IL230447A (uk)
JO (1) JO3249B1 (uk)
MA (1) MA35263B1 (uk)
MX (2) MX359856B (uk)
MY (1) MY173454A (uk)
PE (1) PE20141939A1 (uk)
PH (1) PH12014500026B1 (uk)
SI (1) SI2731946T1 (uk)
TN (1) TN2013000530A1 (uk)
TW (1) TWI589576B (uk)
UA (1) UA113409C2 (uk)
WO (2) WO2013010679A1 (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
CN103601748B (zh) * 2013-10-17 2016-11-02 上海交通大学 羟烷基化杂环硼酸酯及其制备方法、用途
WO2017201364A1 (en) 2016-05-20 2017-11-23 Vanda Pharmaceuticals Inc. Method for improving or enhancing cognition
CN110520110A (zh) * 2017-03-08 2019-11-29 阿瑞雅德制药公司 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂
WO2019084459A1 (en) 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
EP3981768A4 (en) 2019-06-06 2023-07-12 Genfleet Therapeutics (Shanghai) Inc. POLYMORPH OF A CDK9 INHIBITOR, METHOD FOR PREPARING THE POLYMORPH AND USE THEREOF
US20230381169A1 (en) 2020-11-25 2023-11-30 Vanda Pharmaceuticals Inc. Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
AU2003302218A1 (en) 2002-05-16 2004-06-18 Genelabs Technologies, Inc Aryl and heteroaryl compounds as antibacterial and antifungal agents
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2004325725A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
MX2009011998A (es) 2007-05-10 2009-11-19 Pfizer Ltd Derivados de azetidina y su uso como antagonistas de prostaglandina e2.
JP2010530427A (ja) 2007-06-21 2010-09-09 シェーリング コーポレイション 多環式グアニン誘導体およびその使用方法
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2430011A1 (en) 2009-05-15 2012-03-21 Novartis AG 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
JP2012533601A (ja) * 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2011048091A1 (en) 2009-10-21 2011-04-28 Glaxo Group Limited Process for preparing a phenylalanine derivative
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
KR20180014854A (ko) * 2012-12-11 2018-02-09 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성의 예측 바이오마커
US20150313884A1 (en) * 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists

Also Published As

Publication number Publication date
HUE031256T2 (en) 2017-06-28
IL250353A0 (en) 2017-03-30
WO2013010679A1 (en) 2013-01-24
IL230447A (en) 2017-02-28
AU2012285943A1 (en) 2014-01-23
KR101846770B1 (ko) 2018-04-09
PH12014500026A1 (en) 2014-02-17
EP3075732B1 (en) 2018-09-12
WO2013010916A1 (en) 2013-01-24
MA35263B1 (fr) 2014-07-03
CN103717596B (zh) 2017-11-21
HK1194069A1 (zh) 2014-10-10
EP2731946B1 (en) 2016-09-14
EP3075732A3 (en) 2017-01-04
JP2014520824A (ja) 2014-08-25
AR087164A1 (es) 2014-02-26
KR20170002699A (ko) 2017-01-06
US20180009801A1 (en) 2018-01-11
PH12014500026B1 (en) 2018-03-23
JP6263469B2 (ja) 2018-01-17
GT201400007A (es) 2015-02-19
CA2841546A1 (en) 2013-01-24
EP3075732A2 (en) 2016-10-05
CN103717596A (zh) 2014-04-09
CA2841546C (en) 2020-01-14
SI2731946T1 (sl) 2017-04-26
US9365565B2 (en) 2016-06-14
TWI589576B (zh) 2017-07-01
US20140220125A1 (en) 2014-08-07
US9802931B2 (en) 2017-10-31
BR112014000907A2 (pt) 2017-06-13
MY173454A (en) 2020-01-26
MX359856B (es) 2018-10-12
KR20140034309A (ko) 2014-03-19
JO3249B1 (ar) 2018-09-16
CO6852078A2 (es) 2014-01-30
ES2611950T3 (es) 2017-05-11
NZ619574A (en) 2015-12-24
EP2731946A1 (en) 2014-05-21
AU2012285943B2 (en) 2016-03-17
MX348306B (es) 2017-06-06
CL2014000119A1 (es) 2014-07-25
TN2013000530A1 (en) 2015-03-30
MX2014000619A (es) 2014-02-27
CN107602552A (zh) 2018-01-19
JP2016185963A (ja) 2016-10-27
TW201302740A (zh) 2013-01-16
US20160145253A1 (en) 2016-05-26
US10421755B2 (en) 2019-09-24
KR20180037310A (ko) 2018-04-11
PE20141939A1 (es) 2014-12-05
JP6355676B2 (ja) 2018-07-11
EA201490283A1 (ru) 2014-06-30
IL230447A0 (en) 2014-03-31
HK1249505A1 (zh) 2018-11-02
EA025477B1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA201490283A1 (ru) Соли азабициклических диариловых эфиров и способы их получения или получения их предшественников
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
PH12015502615B1 (en) Chemical compounds
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
EA201401351A1 (ru) Производные бензимидазол-пролина
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
PH12015501398A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
PH12015501609A1 (en) Phenicol antibacterials
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
PH12014501056A1 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
IN2015DN02109A (uk)
HK1201839A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands
HK1219723A1 (zh) 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process